CN102836172B - Powder combination containing glucose - Google Patents
Powder combination containing glucose Download PDFInfo
- Publication number
- CN102836172B CN102836172B CN201210348873.2A CN201210348873A CN102836172B CN 102836172 B CN102836172 B CN 102836172B CN 201210348873 A CN201210348873 A CN 201210348873A CN 102836172 B CN102836172 B CN 102836172B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- angle
- repose
- sodium citrate
- funnel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 81
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 30
- 239000008103 glucose Substances 0.000 title abstract description 30
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims description 132
- 238000000034 method Methods 0.000 claims description 69
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 62
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 62
- 239000002245 particle Substances 0.000 claims description 51
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 46
- 239000001509 sodium citrate Substances 0.000 claims description 45
- 229960001031 glucose Drugs 0.000 claims description 44
- 239000000463 material Substances 0.000 claims description 31
- 239000001103 potassium chloride Substances 0.000 claims description 31
- 235000011164 potassium chloride Nutrition 0.000 claims description 31
- 239000011780 sodium chloride Substances 0.000 claims description 31
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 19
- 239000011734 sodium Substances 0.000 abstract description 3
- 229910052708 sodium Inorganic materials 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical group O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 229960000673 dextrose monohydrate Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Sample | RSD | Sample | RSD | Sample | RSD | Sample | RSD |
R1 | 2.93 | R9-7 | 3.34 | R10-3 | 7.92 | R10-17 | 15.9 |
R2 | 3.28 | R9-8 | 3.92 | R10-4 | 3.22 | R10-18 | 8.87 |
R3 | 2.78 | R9-9 | 2.67 | R10-5 | 1.93 | R11-1 | 15.3 |
R4 | 3.82 | R9-10 | 1.87 | R10-6 | 3.29 | R11-2 | 16.6 |
R5 | 2.26 | R9-11 | 4.07 | R10-7 | 2.02 | R11-3 | 9.31 |
R6 | 4.02 | R9-12 | 7.78 | R10-8 | 2.89 | R11-4 | 7.52 |
R7 | 3.23 | R9-13 | 8.42 | R10-9 | 4.11 | R11-5 | 4.21 |
R8 | 2.93 | R9-14 | 9.73 | R10-10 | 3.20 | R11-6 | 3.11 |
R9-1 | 17.2 | R9-15 | 12.5 | R10-11 | 2.73 | R11-7 | 2.98 |
R9-2 | 13.9 | R9-16 | 14.1 | R10-12 | 8.02 | R11-8 | 3.36 |
R9-3 | 7.75 | R9-17 | 16.3 | R10-13 | 8.97 | R11-9 | 2.34 |
R9-4 | 3.92 | R9-18 | 9.53 | R10-14 | 10.8 | R12-1 | 3.28 |
R9-5 | 4.11 | R10-1 | 16.4 | R10-15 | 12.3 | R12-2 | 2.08 |
R9-6 | 2.87 | R10-2 | 14.6 | R10-16 | 13.9 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210348873.2A CN102836172B (en) | 2012-09-20 | 2012-09-20 | Powder combination containing glucose |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210348873.2A CN102836172B (en) | 2012-09-20 | 2012-09-20 | Powder combination containing glucose |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102836172A CN102836172A (en) | 2012-12-26 |
CN102836172B true CN102836172B (en) | 2015-04-29 |
Family
ID=47364075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210348873.2A Active CN102836172B (en) | 2012-09-20 | 2012-09-20 | Powder combination containing glucose |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102836172B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103610692B (en) * | 2013-12-05 | 2015-11-18 | 厦门恩成制药有限公司 | A kind of preparation method of low-permeability oral rehydration salt |
CN105457654B (en) * | 2015-12-14 | 2018-06-19 | 厦门宇净环保科技有限公司 | Catalyst of room temperature catalytic oxidation removing formaldehyde and preparation method thereof |
-
2012
- 2012-09-20 CN CN201210348873.2A patent/CN102836172B/en active Active
Non-Patent Citations (2)
Title |
---|
胡荣峰.粉碎、过筛与混合.《工业药剂学》.中国中医药出版社,2010,第202-203、207-209页. * |
韩树荣.口服补液盐.《铁路红十字救护员培训教材》.中国铁道出版社,2010,第37页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102836172A (en) | 2012-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102824362B (en) | Medicine composition of oral rehydration salt | |
CN101766648B (en) | Polyethylene glycol electrolyte granular preparation and production method | |
CN103610692B (en) | A kind of preparation method of low-permeability oral rehydration salt | |
CN102133225B (en) | Compound polyethylene glycol electrolyte pulvis and preparation method thereof | |
JP2013544287A (en) | Capsule preparation and powder preparation containing lanthanum compound | |
CN102836172B (en) | Powder combination containing glucose | |
CN106491539A (en) | A kind of lamotrigine dry suspension and preparation method thereof | |
CN102824361B (en) | Composition containing glucose | |
Sura et al. | Design and evaluation of liquisolid compacts of nebivolol hydrochloride | |
CN107412177A (en) | 3d printing hydrochlorothiazide tablets and preparation method thereof | |
CN102824360B (en) | Powder composition containing glucose and preparation method thereof | |
Lakshmi et al. | Formulation and Evaluation of Oral Disintegrating Tablets of Lamotrigine Solid Dispersions: Oral dispersible tablets | |
CN107028912A (en) | A kind of preparation method of Irbesartan Capsules | |
CN114366757A (en) | Compound polyethylene glycol electrolyte and preparation method thereof | |
CN104188914B (en) | Amoxicillin powder and its production technology | |
CN102488667A (en) | Glimepiride tablet and preparation method thereof | |
CN103948562B (en) | A kind of Desloratadine capsule and preparation method thereof | |
CN112741819A (en) | Fluoxetine hydrochloride capsule and preparation method thereof | |
Anusha et al. | Formulation and Evaluation of Immediate-Release Tablets of EdoxabanTosylate | |
CN109966262A (en) | Lenalidomide pharmaceutical composition | |
CN107569465A (en) | A kind of Nifedipine sustained release tablets and preparation method thereof | |
CN106265731A (en) | The preparation method of ferrous sulfate matrix type sustained-release dropping pill | |
Isbera et al. | Quality control of Warfarin Sodium tablets marketed in Syria | |
EP2796130A2 (en) | Immediate release tablets of rasagiline hemitartrate | |
CN101474167A (en) | Preparation method of estradiol capsule for vagina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: XI'AN ANJIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG WEI Effective date: 20150909 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150909 Address after: 710400 Shaanxi city of Xi'an Province pharmaceutical Zhouzhi County Road No. 1 Patentee after: XI'AN ANJIAN PHARMACEUTICAL Co.,Ltd. Address before: 510200 No. 40, Po Gang straight street, Haizhuqu District, Guangdong, Guangzhou Patentee before: Wang Wei |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 710404 No. 4 Jicai South Road, Jixian Industrial Park, Zhouzhi County, Xi'an City, Shaanxi Province Patentee after: XI'AN ANJIAN PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: 710400 No.1 Yaochang Road, Zhouzhi County, Xi'an City, Shaanxi Province Patentee before: XI'AN ANJIAN PHARMACEUTICAL Co.,Ltd. Country or region before: China |